OSE Immunotherapeutics SA announced that at its Combined General Shareholders' Meeting held on June 22, 2023. They approved the appointment of Eric Leire as a new independent Director and of Anne-Laure Autret-Cornet, Chief Financial Officer, as Director representing the employee shareholders.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.56 EUR | -0.71% | +3.35% | +29.91% |
Apr. 17 | OSE: licensing agreement with AbbVie enters into force | CF |
Apr. 17 | OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.91% | 128M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- OSE Stock
- News OSE Immunotherapeutics
- OSE Immunotherapeutics SA Appoints Eric Leire as A New Independent Director and Anne-Laure Autret-Cornet as Director